Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 851 - 875 of 1353 in total

Paclitaxel

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as...
Approved
Vet approved
Matched Synonyms: … Paclitaxel protein-bound particles for injection suspension …
Matched Description: … It is available as an intravenous solution for injection and the newer formulation contains albumin-bound ... Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in …
Matched Categories: … Amino Acids, Peptides, and Proteins ... paclitaxel and encequidar ... Antineoplastic and Immunomodulating Agents …
Matched Products: … Aclipak Concentrate for Solution for Infusion 6mg/ ml ... FONKOPAC CONCENTRATE FOR SOLUTION FOR INFUSION 6MG/ML ... ACLIPAK 6 MG/ ML CONCENTRATE FOR SOLUTION FOR INFUSION …

Panitumumab

Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … Vectibix Concentrate for Solution for Infusion 100 mg/vial ... Vectibix 100mg Concentrate for Solution for Infusion …

Benralizumab

Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R,...
Approved
Investigational
Matched Description: … It is an afucosylated IgG which gives it high affinity for the FcγRIIIα receptor in natural killer cells ... , macrophages and neutrophils. ... global biologic research and development arm. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs for Obstructive Airway Diseases …
Matched Products: … Fasenra 30 mg solution for injection in pre-filled syringe ... Fasenra 30mg Solution for Injection in Pre-filled Pen ... FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN) …

Glycyl-L-a-Aminopimelyl-E-(D-2-Aminoethyl)Phosphonate

Experimental
Matched Name: … Glycyl-L-a-Aminopimelyl-E-(D-2-Aminoethyl)Phosphonate …

Eravacycline

Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic...
Approved
Investigational
Matched Description: … Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for ... carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens [A38683]. ... tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and …
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL …

Cimicoxib

Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.
Investigational
Matched Description: … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and …
Matched Products: … Cimalgex 30mg chewable tablets for dogs ... Cimalgex 80mg chewable tablets for dogs ... Cimalgex 8mg chewable tablets for dogs …

Etelcalcetide

Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
Approved
Investigational
Matched Description: … Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism ( ... Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing …
Matched Categories: … Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins …
Matched Products: … PARSABIV SOLUTION FOR INJECTION 5 mg/mL ... Parsabiv 5mg solution for injection ... PARSABIV SOLUTION FOR INJECTION 2.5 mg/0.5 mL …

Hydrocortisone succinate

Approved
Matched Categories: … Hydrocortisone and derivatives ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … SOLU-CORTEF FOR INJECTION 100 mg/vial ... Hydrocortisone Sodium Succinate for Injection ... HYDROCORTISONE SODIUM SUCCINATE FOR INJECTION B. P …

Canakinumab

Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy...
Approved
Investigational
Matched Description: … Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older ... part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and ... and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Products: … Ilaris Powder for Solution for Injection 150mg/vial ... ILARIS 150MG POWDER FOR SOLUTION FOR INJECTION …

Gemtuzumab ozogamicin

Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. The antibody is specifically...
Approved
Investigational
Matched Description: … It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who ... candidates for cytotoxic chemotherapy [A98]. ... By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL …

Inotuzumab ozogamicin

Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects. Inotuzumab ozogamicin was first...
Approved
Investigational
Matched Description: … [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly ... [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL …

Durvalumab

Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and ... ] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage small …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML ... IMFINZI CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION 50 MG/ML …

Avalglucosidase alfa

Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase (GAA) enzyme. GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. In Pompe disease, the...
Approved
Investigational
Matched Description: … Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe ... , especially in smooth, cardiac, and skeletal muscle cells. ... muscle weakness, which leads to premature death and debilitating effects on people’s lives. …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Matched Products: … NEXVIAZYME 100mg Powder for Concentrate for Solution for Infusion …

Denosumab

Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for ... fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men ... [A263071] Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs for Treatment of Bone Diseases ... Drugs Affecting Bone Structure and Mineralization …
Matched Products: … XGEVA 120mg Solution for Injection ... XGEVA Solution for Injection 120 mg/vial ... Prolia Solution for Injection 60mg Pre-filled Syringe …

Deferoxamine

Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Approved
Investigational
Matched Description: … It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. …
Matched Products: … Desferal 500mg Powder for Solution for Injection ... Deferoxamine Mesylate for Injection ... DBL DESFERRIOXAMINE MESYLATE FOR INJECTION BP 500 mg/vial …

Interferon beta-1a

Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Matched Products: … Rebif 22mcg/0.5ml solution for injection ... Rebif 44mcg/0.5ml solution for injection ... Rebif Solution for Injection in Cartridge 22mcg/0.5ml …

Tigecycline

Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
Approved
Matched Description: … Food and Drug Administration (FDA) on June 17, 2005. ... Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil …
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … Tigaciv 50mg Lyophilized Powder for Concentrate for Solution for Infusion ... TIGECYCLINE SANDOZ POWDER FOR SOLUTION FOR INFUSION 50 MG PER VIAL ... TIGAR 50 (Tigecycline Powder for Solution for Infusion 50mg/Vial) …

Sodium zirconium cyclosilicate

Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval...
Approved
Investigational
Matched Description: … [L2933] It is administered orally and is odorless, tasteless, and stable at room temperature. ... [L2933] The treatment effect was maintained for up to 12 months.[L2933] ... Approval of the medication is supported by data from three double-blind, placebo-controlled trials and …
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia ... Potassium Binder ... Potassium-removing Agents …
Matched Products: … LOKELMA POWDER FOR ORAL SUSPENSION 5G ... LOKELMA POWDER FOR ORAL SUSPENSION 10G ... Lokelma 5g Powder for Oral Suspension …

Decitabine

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis.[A215082, A215092] Among treatment options, nucleoside analogues such as...
Approved
Investigational
Matched Description: … approved by the FDA for the treatment of MDS on February 5, 2006. ... and related downstream therapeutic benefits. ... presentation, including neutropenia and thrombocytopenia. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Matched Products: … DACOGEN (Decitabine) 50 mg Powder for Concentrate for Solution for Infusion ... Redtibin (Decitabine) Powder for Injection 50mg/vial …

Daunorubicin

A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Approved
Matched Description: … , used in treatment of leukemia and other neoplasms. ... A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others …
Matched Categories: … Anthracyclines and Related Substances ... cytarabine and daunorubicin ... Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
Matched Products: … DAUNOCIN FOR INJ ... DAUNOCIN FOR INJECTION 20 mg/vial ... DAUNOBLASTINA FOR INJECTION 20 mg/vial …

Izokibep

Izokibep is under investigation in clinical trial NCT05623345 (Psoriatic Arthritis Study of Izokibep).
Investigational
Matched Synonyms: … DERIVED FROM THE IMMUNOGLOBULIN (IG)-BINDING Z-DOMAIN OF STAPHYLOCOCCAL PROTEIN A (SPA), ENGINEERED FOR …

Ixabepilone

Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is...
Approved
Investigational
Matched Description: … Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
Matched Products: … IXEMPRA FOR INJECTION 15 MG ... IXEMPRA (FOR INJECTION 15 MG) ... IXEMPRA FOR INJECTION 45 MG …

Atosiban

Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish...
Approved
Investigational
Matched Description: … Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant ... Atosiban is an inhibitor of the hormones oxytocin and vasopressin. ... Although initial studies suggested it could be used as a nasal spray and hence would not require hospital …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Genito Urinary System and Sex Hormones ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … TRACTOCILE 7.5MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION ... TRACTOCILE (7.5 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION) ... TRACTOCILE 7.5MG/ML,SOLUTION FOR INJECTION …

Guselkumab

Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in...
Approved
Investigational
Matched Description: … In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological ... market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis. ... Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …
Matched Products: … TREMFYA 100MG/ML SOLUTION FOR INJECTION ... Tremfya One-Press 100mg/ml Solution for Injection ... TREMFYA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML …

Emicizumab

Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable...
Approved
Investigational
Matched Description: … Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017. ... Ltd. and co-developed with Roche and Genentech.[L1015] ... it has the capacity to bind simultaneously to activated Factor IX and Factor X. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …
Matched Products: … HEMLIBRA 30MG/ML SOLUTION FOR INJECTION ... HEMLIBRA 150MG/ML SOLUTION FOR INJECTION ... HEMLIBRA SOLUTION FOR INJECTION 30MG/ML …
Displaying drugs 851 - 875 of 1353 in total